A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Pregabalin (Lyrica)

indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for the treatment of partial-onset seizures in p....

First FDA approval2004-12-30
Generic availableYes · 28 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$382.3M in CY2024 Part D spend11.6M claims · 2.8M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.046/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.046
Across all dosage forms in distribution.
Highest NADAC
$0.046
Range is tight.
Plans with PA
597 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Pregabalin used for?

indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for the treatment of partial-onset seizures in p....

Is there a generic for Pregabalin?

Yes. 192 ANDAs filed at FDA, 28 generic manufacturers currently shipping.

How much does my plan pay for Pregabalin?

Across 329 Part D plans, Pregabalin averages $0.046/unit (NADAC). Lowest available: $0.046/unit. Highest in distribution: $0.046/unit.

Is Pregabalin on the FDA shortage list?

No. Pregabalin is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Anticonvulsant / Neuropathic Pain Agent1 alternative in D1
01
Gabapentin
Brand: GABARONE
$0.021Lowest NADAC
28Generic mfrs
$879.9MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.